BioCentury This Week
BioCentury This Week

Nov 20, 2026 · 29 min

UK regulators test faster, more flexible biotech pathways

Ep. 399 - Key themes from Jefferies. Plus: U.K. regulatory innovation

The episode connects regulatory reform, non-animal methods, AI-enabled laboratories and geopolitical investment rules to the future of drug development.

3 key takeaways
  1. 1The UK is using rare-disease pathways and regulatory coordination to position itself as a hub for life sciences innovation.
  2. 2AI-designed medicines are increasing demand for automated wet labs that can scale synthesis, testing and data generation.
  3. 3The panel questions whether Isomorphic Labs’ reported valuation reflects AI’s promise or the clinical and commercial hurdles ahead.

Don't miss

The panel weighs whether Isomorphic Labs’ reported approximately $50 billion valuation can be justified by AI’s potential before clinical and commercial results arrive.

The brief

At London Life Sciences Week, the panel examines the UK’s post-Brexit effort to streamline regulation, convene global regulators and speed development for rare diseases.

A parliamentary discussion on non-animal methods raises a central question: can new approach methodologies accelerate preclinical work without obscuring uncertainty around complex new modalities?

AI drug design is expanding the bottleneck in the opposite direction: automated wet labs must generate enough synthesis, testing and experimental data to keep pace with computation.

Investor reactions to the COINS Act show how restrictions on U.S. investment in China-based companies could complicate European funds, licensing strategies and biotech collaboration.

The sharpest debate concerns Isomorphic Labs’ reported $5 billion financing at an approximately $50 billion valuation, weighed against the clinical and commercial proof still required.

The episode’s broader takeaway is that biotech innovation depends on several systems moving together: regulators, experimental infrastructure, capital and evidence of real-world drug impact.

What was said on this episode

21 statements · 11 positive · 6 negative · 2 mixed · 2 neutral

  1. Simone Fishburnon MHRA regulatory innovationPositive3:46

    Lawrence Tallon is advancing sorely needed regulatory innovation through MHRA convening.

    “I think he's trying to become a convener and... advanced regulatory innovation here, which I think is sorely needed.”

    Listen at 3:46

  2. Jackie Mulryneon MHRA post-Brexit regulatory flexibilityPositive4:29

    The MHRA has substantial regulatory flexibility after Brexit.

    “they've got this real flexibility post-Brexit”

    Listen at 4:29

  3. Jackie Mulryneon MHRA regulatory frameworkNeutral4:52

    The MHRA pursues convergence where possible and purposeful regulatory divergence.

    “their buzzwords are kind of convergence where possible, but divergence with a purpose.”

    Listen at 4:52

  4. Jackie Mulryneon FDA and MHRA rare-disease policyPositive5:32

    The FDA and MHRA are developing streamlined rare-disease regulatory policies.

    “their new streamlined policy they're trying to do on rare diseases”

    Listen at 5:32

  5. Jackie Mulryneon MHRA innovation-attraction frameworkPositive7:27

    The MHRA is creating a framework to attract innovative products to the UK.

    “they're trying to put the framework in place so that companies will come here and use us for that purpose.”

    Listen at 7:27

  6. Steve Yangon Drug-development speed to patientsPositive9:33

    Accelerating medicines to patients is a dominant industry priority.

    “the speed to patients is almost an overarching theme across the various small group meetings I have with customers and also industry panels.”

    Listen at 9:33

  7. Steve Yangon Complex new drug modalitiesNegative10:16

    Complex new drug modalities have less well-known safety profiles.

    “their safety profile is less well known.”

    Listen at 10:16

  8. Simone Fishburnon New-pathway biologyNegative11:07

    New-pathway biology is unlikely to move directly into human testing soon.

    “if you've got new pathway biology, the idea of going with new pathway biology straight into humans, you know, that's got to be a very long way off.”

    Listen at 11:07

  9. Jackie Mulryneon Non-animal methodsMixed11:19

    NAMs may be suitable for follow-on or non-first-in-class products.

    “you can use NAMS for some products and maybe that's a follow-on product or where it's not going to be a first in class”

    Listen at 11:19

  10. Steve Yangon AIDD experimental data demandPositive16:24

    AIDD customers require ten times more experimental plate capacity than typical biotech programs.

    “We are talking about a 10x jump”

    Listen at 16:24

  11. Steve Yangon AIDD experimental data demandPositive16:50

    A global AIDD leader wants fifty times more capacity beyond the existing tenfold increase.

    “They want another 50x on top of this 10x.”

    Listen at 16:50

  12. Steve Yangon AI drug discoveryMixed17:16

    AI sharply increases design and analysis capacity, while physical molecule-making remains necessary.

    “the ability to design, jump through the roof, the ability to analyze, jump through the roof, thanks to the AI and agent. But someone has to make them.”

    Listen at 17:16

  13. Steve Yangon Wet laboratoriesPositive17:40

    AI-driven discovery creates strong demand for automated, streamlined wet laboratories.

    “there is a strong need and opportunity for the wet labs, which is what we try to beef up, automate, and streamline.”

    Listen at 17:40

  14. Simone Fishburnon COINS ActNegative19:30

    COINS Act provisions would prevent U.S. investors from taking equity in China-based companies.

    “the US investors are very, very annoyed about the Coins Act or the provisions that they will not be able to take equity in China-based companies.”

    Listen at 19:30

  15. Simone Fishburnon BiotechnologyNegative20:07

    European investors may need U.S. crossover or U.S.-based investors for NASDAQ listings.

    “if they ever want to go public on NASDAQ, you know, a premise that they have to do. They're not going to be able to do that if they don't have U.S. crossovers or U.S.-based investors.”

    Listen at 20:07

  16. Stephen Hansenon COINS ActNegative20:33

    European investors with U.S. LPs may fall under COINS Act restrictions on China NUCO deals.

    “if you're a European investor and you have a U.S. LP, then if you do a China NUCO deal, Because the economic gain would flow back to a U.S. entity, you are then ensnared in the Coins Act in the same way that a U.S. investor would be.”

    Listen at 20:33

  17. Josh Berlinon Pharmaceutical licensing dealsPositive21:37

    Straight licensing deals would remain permissible under the proposed COINS Act wording.

    “straight licensing deals would be just fine.”

    Listen at 21:37

  18. Jackie Mulryneon Pharmaceutical collaborationPositive23:57

    High clinical-development speed and costs will drive increasing collaboration among pharma companies.

    “everyone's trying to work out what to do and whether that's collaborate or because it's not... very easy to compete, given the speed and the cost of doing clinical development. So everyone wants to collaborate in some way. So I think that will only grow.”

    Listen at 23:57

  19. Simone Fishburnon AI drug-discovery probability of successNegative26:45

    Raising drug-development success probability from 10% to 20% would not justify the required molecule count.

    “10% to 20% does not get you to the number of molecules.”

    Listen at 26:45

  20. Simone Fishburnon AI drug-discovery probability of successPositive26:54

    AI drug discovery would need approximately 90% success probability for transformative valuation claims.

    “you've got to get to 90%.”

    Listen at 26:54

  21. Stephen Hansenon Heng RheeNeutral27:36

    Heng Rhee is valued around $50 billion with $4 billion revenue and extensive clinical activity.

    “Heng Rhee, which is also valued at around $50 billion and has, you know, $4 billion in annual revenues, over 100 molecules in the clinic, I think, and like 400 clinical trials ongoing.”

    Listen at 27:36

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Weekly email

State of the Pod, every Monday

The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.

Listen to the full episode and explore every guest, topic, and moment on PodLume.

UK regulators test faster, more flexible biotech pathways · PodLume